Prostate cancer trials in China

In China 252 Also abroad 1481

252 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis
Where
Beijing
Age
18 years to 85 years
People
592
Run by
Peking University First Hospital
See details and how to joinNCT07460843
Phase 1Not yet taking people in China
A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer
Where
Beijing
Age
18 years and over
People
65
Run by
Gan & Lee Pharmaceuticals.
See details and how to joinNCT07468396
Phase 2Taking people
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Where
Nanjing, Tianjin
Age
18 years to 80 years
People
218
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07230106
No phaseNot yet taking people in China
Rezvilutamide for High-Risk Prostate Cancer After Surgery
Where
Fuzhou
Age
18 years to 95 years
People
33
Run by
Fujian Medical University Union Hospital
See details and how to joinNCT07444983
Phase 1/2Taking people
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Where
Beijing
Age
8 years to 85 years
People
85
Run by
Essen Biotech
See details and how to joinNCT07410494
Phase 1/2Taking people
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Where
Beijing
People
83
Run by
Essen Biotech
See details and how to joinNCT07410676
Early phase 1Not yet taking people in China
Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Where
Shanghai
Age
18 years to 85 years
People
40
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07389174
Early phase 1Not yet taking people in China
Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Where
Shanghai
Age
18 years to 85 years
People
10
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07389187
Phase 3Taking people
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Where
Shanghai
Age
18 years and over
People
370
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07311694
Phase 2Not yet taking people in China
PSMA-Targeted Intraoperative Fluorescent Imaging Agents (DGPR1008): Validation Across Different Time Windows
Where
Qingdao
Age
18 years and over
People
27
Run by
Haitao Niu, MD
See details and how to joinNCT07387510
Early phase 1Not yet taking people in China
Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Where
Beijing, Mianyang
Age
18 years and over
People
15
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07381582
No phaseTaking people
The Development and Validation of MRI-AI-based Predictive Models for csPCa
Where
Beijing
People
3,000
Run by
Peking University First Hospital
See details and how to joinNCT06842264
No phaseNot yet taking people in China
Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer
Where
Guangzhou
Age
18 years and over
People
150
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07376057
Early phase 1Taking people
Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer
Where
Beijing
Age
18 years and over
People
10
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07156045
Phase 1/2Taking people
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer
Where
Fuzhou
Age
18 years to 90 years
People
6
Run by
First Affiliated Hospital of Fujian Medical University
See details and how to joinNCT07363382
Phase 1/2Taking people
Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Where
Fuzhou
Age
18 years to 90 years
People
9
Run by
First Affiliated Hospital of Fujian Medical University
See details and how to joinNCT07363486
Early phase 1Taking people
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Where
Beijing
Age
18 years and over
People
15
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07298239
Phase 2/3Taking people
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Where
Qingdao, Shanghai
Age
40 years to 75 years
People
300
Run by
Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT03258320
Phase 1Taking people
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Where
Hangzhou, Shanghai, Wuhan, Zhengzhou
Age
18 years and over
People
200 worldwide
Run by
Phrontline Biopharma
See details and how to joinNCT07181473
No phaseTaking people
Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis
Where
Hefei
Age
50 years and over
People
2,000
Run by
Anhui Medical University
See details and how to joinNCT07112599
Phase 1/2Taking people
A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
Where
Tianjin, Wuxi
Age
18 years and over
People
55
Run by
Yunhe Pharmaceutical (Tianjin) Co., Ltd
See details and how to joinNCT06970119
No phaseTaking people
Adaptive Radiotherapy for Genitourinary Cancers
Where
Beijing
Age
18 years and over
People
60
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07324798
No phaseNot yet taking people in China
Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study
Where
Nanjing
Age
18 years to 85 years
People
30
Run by
Zhongda Hospital
See details and how to joinNCT07311915
No phaseTaking people
Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing
Where
Beijing
Age
18 years to 85 years
People
3,000
Run by
Peking University First Hospital
See details and how to joinNCT07319923
Phase 1/2Taking people
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Where
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Mianyang, Nanchang, Ningbo, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xiamen, Xi’an, Yantai, Zhengzhou
Age
18 years and over
People
84
Run by
Hinova Pharmaceuticals Inc.
See details and how to joinNCT06155084